Alectinib induces marked red cell spheroacanthocytosis in a near-ubiquitous fashion and is associated with reduced eosin-5-maleimide binding-Reference-Cited by-同舟云学术

Alectinib induces marked red cell spheroacanthocytosis in a near-ubiquitous fashion and is associated with reduced eosin-5-maleimide binding

Published:2021-08 Issue:5 Volume:53 Page:608-612
ISSN:0031-3025
Container-title:Pathology
language:en
Short-container-title:Pathology

Author:

Kuzich James A.^ORCID,Heynemann Sarah^ORCID,Geoghegan Niall^ORCID,Evelyn Cindy,O'Mahoney Susan,Wilson Susan,Campbell Janine,Rogers Kelly,Solomon Benjamin,Westerman David,Pasricha Sant-Rayn

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference13 articles.

1. Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial;Hida;Lancet,2017

2. Alectinib versus crizotinib in untreated ALK -positive non-small-cell lung cancer;Peters;N Engl J Med,2017

3. The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis;Fan;Oncotargets Ther,2018

4. Eosin-5-maleimide binding to band 3 and Rh-related proteins forms the basis of a screening test for hereditary spherocytosis;King;Br J Haematol,2004

5. Lattice light-sheet microscopy: imaging molecules to embryos at high spatiotemporal resolution;Chen;Science,2014

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epithelioid inflammatory myofibroblastic sarcoma treated with Alectinib: a case report and literature review;Frontiers in Oncology;2024-08-30

2. Changes in Red Cell Morphology and Haematological Laboratory Parameters Associated With Alectinib;Journal of Clinical Laboratory Analysis;2024-07

3. Alectinib-Induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma: Case Report and Literature Review;Case Reports in Clinical Medicine;2024

4. Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors;ESMO Open;2023-06

5. Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report;OncoTargets and Therapy;2023-01